世界の腫瘍特異抗原市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Tumor-Specific Antigen Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4991 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、腫瘍特異抗原の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（コーディング領域、ノンコーディング領域）、用途別市場規模（創薬、診断、臨床・基礎研究、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・腫瘍特異抗原の市場動向 ・企業の競争状況、市場シェア ・腫瘍特異抗原の種類別市場規模と予測2016-2027（コーディング領域、ノンコーディング領域） ・腫瘍特異抗原の用途別市場規模と予測2016-2027（創薬、診断、臨床・基礎研究、その他） ・腫瘍特異抗原の北米市場規模2016-2027（アメリカ、カナダ） ・腫瘍特異抗原の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・腫瘍特異抗原のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・腫瘍特異抗原の中南米市場規模2016-2027（メキシコ、ブラジル） ・腫瘍特異抗原の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Agilent Technologies、Creative Diagnostics、Go Therapeutics、Lee Biosolutions、Bio-Rad、Biomrieux、Caris Life Sciences、Roche、Abcam、Merck Group、PerkinElmer、OriGene Technologies） ・結論

Tumor-specific Antigen is a new Antigen that is expressed on the surface of certain Tumor cells but not on normal cells.Such antigens may be present in tumors of the same tissue type in different individuals.Tumor-specific antigens help the body develop an immune response to cancer cells.They could be used as potential targets for targeted therapy or immunotherapy to help improve the body’s immune system to kill more cancer cells.Tumor-specific antigens can also be used in laboratory tests to help identify certain types of cancer.

Market Analysis and Insights: Global Tumor-Specific Antigen Market
The global Tumor-Specific Antigen market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Tumor-Specific Antigen market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Tumor-Specific Antigen market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Tumor-Specific Antigen market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Tumor-Specific Antigen market.

Global Tumor-Specific Antigen Scope and Market Size
Tumor-Specific Antigen market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Tumor-Specific Antigen market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Coding Region
Non-Coding Region

Segment by Application
Drug Discovery and Development
Diagnostics
Clinical and Basic Research
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Agilent Technologies
Creative Diagnostics
Go Therapeutics
Lee Biosolutions
Bio-Rad
Biomrieux
Caris Life Sciences
Roche
Abcam
Merck Group
PerkinElmer
OriGene Technologies

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tumor-Specific Antigen Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Coding Region
1.2.3 Non-Coding Region
1.3 Market by Application
1.3.1 Global Tumor-Specific Antigen Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Drug Discovery and Development
1.3.3 Diagnostics
1.3.4 Clinical and Basic Research
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Tumor-Specific Antigen Market Perspective (2016-2027)
2.2 Tumor-Specific Antigen Growth Trends by Regions
2.2.1 Tumor-Specific Antigen Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Tumor-Specific Antigen Historic Market Share by Regions (2016-2021)
2.2.3 Tumor-Specific Antigen Forecasted Market Size by Regions (2022-2027)
2.3 Tumor-Specific Antigen Industry Dynamic
2.3.1 Tumor-Specific Antigen Market Trends
2.3.2 Tumor-Specific Antigen Market Drivers
2.3.3 Tumor-Specific Antigen Market Challenges
2.3.4 Tumor-Specific Antigen Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Tumor-Specific Antigen Players by Revenue
3.1.1 Global Top Tumor-Specific Antigen Players by Revenue (2016-2021)
3.1.2 Global Tumor-Specific Antigen Revenue Market Share by Players (2016-2021)
3.2 Global Tumor-Specific Antigen Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Tumor-Specific Antigen Revenue
3.4 Global Tumor-Specific Antigen Market Concentration Ratio
3.4.1 Global Tumor-Specific Antigen Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tumor-Specific Antigen Revenue in 2020
3.5 Tumor-Specific Antigen Key Players Head office and Area Served
3.6 Key Players Tumor-Specific Antigen Product Solution and Service
3.7 Date of Enter into Tumor-Specific Antigen Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Tumor-Specific Antigen Breakdown Data by Type
4.1 Global Tumor-Specific Antigen Historic Market Size by Type (2016-2021)
4.2 Global Tumor-Specific Antigen Forecasted Market Size by Type (2022-2027)

5 Tumor-Specific Antigen Breakdown Data by Application
5.1 Global Tumor-Specific Antigen Historic Market Size by Application (2016-2021)
5.2 Global Tumor-Specific Antigen Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Tumor-Specific Antigen Market Size (2016-2027)
6.2 North America Tumor-Specific Antigen Market Size by Type
6.2.1 North America Tumor-Specific Antigen Market Size by Type (2016-2021)
6.2.2 North America Tumor-Specific Antigen Market Size by Type (2022-2027)
6.2.3 North America Tumor-Specific Antigen Market Size by Type (2016-2027)
6.3 North America Tumor-Specific Antigen Market Size by Application
6.3.1 North America Tumor-Specific Antigen Market Size by Application (2016-2021)
6.3.2 North America Tumor-Specific Antigen Market Size by Application (2022-2027)
6.3.3 North America Tumor-Specific Antigen Market Size by Application (2016-2027)
6.4 North America Tumor-Specific Antigen Market Size by Country
6.4.1 North America Tumor-Specific Antigen Market Size by Country (2016-2021)
6.4.2 North America Tumor-Specific Antigen Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Tumor-Specific Antigen Market Size (2016-2027)
7.2 Europe Tumor-Specific Antigen Market Size by Type
7.2.1 Europe Tumor-Specific Antigen Market Size by Type (2016-2021)
7.2.2 Europe Tumor-Specific Antigen Market Size by Type (2022-2027)
7.2.3 Europe Tumor-Specific Antigen Market Size by Type (2016-2027)
7.3 Europe Tumor-Specific Antigen Market Size by Application
7.3.1 Europe Tumor-Specific Antigen Market Size by Application (2016-2021)
7.3.2 Europe Tumor-Specific Antigen Market Size by Application (2022-2027)
7.3.3 Europe Tumor-Specific Antigen Market Size by Application (2016-2027)
7.4 Europe Tumor-Specific Antigen Market Size by Country
7.4.1 Europe Tumor-Specific Antigen Market Size by Country (2016-2021)
7.4.2 Europe Tumor-Specific Antigen Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Tumor-Specific Antigen Market Size (2016-2027)
8.2 Asia-Pacific Tumor-Specific Antigen Market Size by Type
8.2.1 Asia-Pacific Tumor-Specific Antigen Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Tumor-Specific Antigen Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Tumor-Specific Antigen Market Size by Type (2016-2027)
8.3 Asia-Pacific Tumor-Specific Antigen Market Size by Application
8.3.1 Asia-Pacific Tumor-Specific Antigen Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Tumor-Specific Antigen Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Tumor-Specific Antigen Market Size by Application (2016-2027)
8.4 Asia-Pacific Tumor-Specific Antigen Market Size by Region
8.4.1 Asia-Pacific Tumor-Specific Antigen Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Tumor-Specific Antigen Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Tumor-Specific Antigen Market Size (2016-2027)
9.2 Latin America Tumor-Specific Antigen Market Size by Type
9.2.1 Latin America Tumor-Specific Antigen Market Size by Type (2016-2021)
9.2.2 Latin America Tumor-Specific Antigen Market Size by Type (2022-2027)
9.2.3 Latin America Tumor-Specific Antigen Market Size by Type (2016-2027)
9.3 Latin America Tumor-Specific Antigen Market Size by Application
9.3.1 Latin America Tumor-Specific Antigen Market Size by Application (2016-2021)
9.3.2 Latin America Tumor-Specific Antigen Market Size by Application (2022-2027)
9.3.3 Latin America Tumor-Specific Antigen Market Size by Application (2016-2027)
9.4 Latin America Tumor-Specific Antigen Market Size by Country
9.4.1 Latin America Tumor-Specific Antigen Market Size by Country (2016-2021)
9.4.2 Latin America Tumor-Specific Antigen Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Tumor-Specific Antigen Market Size (2016-2027)
10.2 Middle East & Africa Tumor-Specific Antigen Market Size by Type
10.2.1 Middle East & Africa Tumor-Specific Antigen Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Tumor-Specific Antigen Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Tumor-Specific Antigen Market Size by Type (2016-2027)
10.3 Middle East & Africa Tumor-Specific Antigen Market Size by Application
10.3.1 Middle East & Africa Tumor-Specific Antigen Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Tumor-Specific Antigen Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Tumor-Specific Antigen Market Size by Application (2016-2027)
10.4 Middle East & Africa Tumor-Specific Antigen Market Size by Country
10.4.1 Middle East & Africa Tumor-Specific Antigen Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Tumor-Specific Antigen Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Agilent Technologies
11.1.1 Agilent Technologies Company Details
11.1.2 Agilent Technologies Business Overview
11.1.3 Agilent Technologies Tumor-Specific Antigen Introduction
11.1.4 Agilent Technologies Revenue in Tumor-Specific Antigen Business (2016-2021)
11.1.5 Agilent Technologies Recent Development
11.2 Creative Diagnostics
11.2.1 Creative Diagnostics Company Details
11.2.2 Creative Diagnostics Business Overview
11.2.3 Creative Diagnostics Tumor-Specific Antigen Introduction
11.2.4 Creative Diagnostics Revenue in Tumor-Specific Antigen Business (2016-2021)
11.2.5 Creative Diagnostics Recent Development
11.3 Go Therapeutics
11.3.1 Go Therapeutics Company Details
11.3.2 Go Therapeutics Business Overview
11.3.3 Go Therapeutics Tumor-Specific Antigen Introduction
11.3.4 Go Therapeutics Revenue in Tumor-Specific Antigen Business (2016-2021)
11.3.5 Go Therapeutics Recent Development
11.4 Lee Biosolutions
11.4.1 Lee Biosolutions Company Details
11.4.2 Lee Biosolutions Business Overview
11.4.3 Lee Biosolutions Tumor-Specific Antigen Introduction
11.4.4 Lee Biosolutions Revenue in Tumor-Specific Antigen Business (2016-2021)
11.4.5 Lee Biosolutions Recent Development
11.5 Bio-Rad
11.5.1 Bio-Rad Company Details
11.5.2 Bio-Rad Business Overview
11.5.3 Bio-Rad Tumor-Specific Antigen Introduction
11.5.4 Bio-Rad Revenue in Tumor-Specific Antigen Business (2016-2021)
11.5.5 Bio-Rad Recent Development
11.6 Biomrieux
11.6.1 Biomrieux Company Details
11.6.2 Biomrieux Business Overview
11.6.3 Biomrieux Tumor-Specific Antigen Introduction
11.6.4 Biomrieux Revenue in Tumor-Specific Antigen Business (2016-2021)
11.6.5 Biomrieux Recent Development
11.7 Caris Life Sciences
11.7.1 Caris Life Sciences Company Details
11.7.2 Caris Life Sciences Business Overview
11.7.3 Caris Life Sciences Tumor-Specific Antigen Introduction
11.7.4 Caris Life Sciences Revenue in Tumor-Specific Antigen Business (2016-2021)
11.7.5 Caris Life Sciences Recent Development
11.8 Roche
11.8.1 Roche Company Details
11.8.2 Roche Business Overview
11.8.3 Roche Tumor-Specific Antigen Introduction
11.8.4 Roche Revenue in Tumor-Specific Antigen Business (2016-2021)
11.8.5 Roche Recent Development
11.9 Abcam
11.9.1 Abcam Company Details
11.9.2 Abcam Business Overview
11.9.3 Abcam Tumor-Specific Antigen Introduction
11.9.4 Abcam Revenue in Tumor-Specific Antigen Business (2016-2021)
11.9.5 Abcam Recent Development
11.10 Merck Group
11.10.1 Merck Group Company Details
11.10.2 Merck Group Business Overview
11.10.3 Merck Group Tumor-Specific Antigen Introduction
11.10.4 Merck Group Revenue in Tumor-Specific Antigen Business (2016-2021)
11.10.5 Merck Group Recent Development
11.11 PerkinElmer
11.11.1 PerkinElmer Company Details
11.11.2 PerkinElmer Business Overview
11.11.3 PerkinElmer Tumor-Specific Antigen Introduction
11.11.4 PerkinElmer Revenue in Tumor-Specific Antigen Business (2016-2021)
11.11.5 PerkinElmer Recent Development
11.12 OriGene Technologies
11.12.1 OriGene Technologies Company Details
11.12.2 OriGene Technologies Business Overview
11.12.3 OriGene Technologies Tumor-Specific Antigen Introduction
11.12.4 OriGene Technologies Revenue in Tumor-Specific Antigen Business (2016-2021)
11.12.5 OriGene Technologies Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Tumor-Specific Antigen Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Coding Region
Table 3. Key Players of Non-Coding Region
Table 4. Global Tumor-Specific Antigen Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Tumor-Specific Antigen Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Tumor-Specific Antigen Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Tumor-Specific Antigen Market Share by Regions (2016-2021)
Table 8. Global Tumor-Specific Antigen Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Tumor-Specific Antigen Market Share by Regions (2022-2027)
Table 10. Tumor-Specific Antigen Market Trends
Table 11. Tumor-Specific Antigen Market Drivers
Table 12. Tumor-Specific Antigen Market Challenges
Table 13. Tumor-Specific Antigen Market Restraints
Table 14. Global Tumor-Specific Antigen Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Tumor-Specific Antigen Market Share by Players (2016-2021)
Table 16. Global Top Tumor-Specific Antigen Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Tumor-Specific Antigen as of 2020)
Table 17. Ranking of Global Top Tumor-Specific Antigen Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Tumor-Specific Antigen Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Tumor-Specific Antigen Product Solution and Service
Table 21. Date of Enter into Tumor-Specific Antigen Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Tumor-Specific Antigen Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Tumor-Specific Antigen Revenue Market Share by Type (2016-2021)
Table 25. Global Tumor-Specific Antigen Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Tumor-Specific Antigen Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Tumor-Specific Antigen Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Tumor-Specific Antigen Revenue Market Share by Application (2016-2021)
Table 29. Global Tumor-Specific Antigen Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Tumor-Specific Antigen Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Tumor-Specific Antigen Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Tumor-Specific Antigen Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Tumor-Specific Antigen Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Tumor-Specific Antigen Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Tumor-Specific Antigen Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Tumor-Specific Antigen Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Tumor-Specific Antigen Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Tumor-Specific Antigen Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Tumor-Specific Antigen Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Tumor-Specific Antigen Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Tumor-Specific Antigen Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Tumor-Specific Antigen Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Tumor-Specific Antigen Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Tumor-Specific Antigen Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Tumor-Specific Antigen Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Tumor-Specific Antigen Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Tumor-Specific Antigen Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Tumor-Specific Antigen Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Tumor-Specific Antigen Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Tumor-Specific Antigen Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Tumor-Specific Antigen Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Tumor-Specific Antigen Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Tumor-Specific Antigen Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Tumor-Specific Antigen Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Tumor-Specific Antigen Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Tumor-Specific Antigen Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Tumor-Specific Antigen Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Tumor-Specific Antigen Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Tumor-Specific Antigen Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Tumor-Specific Antigen Market Size by Country (2022-2027) & (US$ Million)
Table 61. Agilent Technologies Company Details
Table 62. Agilent Technologies Business Overview
Table 63. Agilent Technologies Tumor-Specific Antigen Product
Table 64. Agilent Technologies Revenue in Tumor-Specific Antigen Business (2016-2021) & (US$ Million)
Table 65. Agilent Technologies Recent Development
Table 66. Creative Diagnostics Company Details
Table 67. Creative Diagnostics Business Overview
Table 68. Creative Diagnostics Tumor-Specific Antigen Product
Table 69. Creative Diagnostics Revenue in Tumor-Specific Antigen Business (2016-2021) & (US$ Million)
Table 70. Creative Diagnostics Recent Development
Table 71. Go Therapeutics Company Details
Table 72. Go Therapeutics Business Overview
Table 73. Go Therapeutics Tumor-Specific Antigen Product
Table 74. Go Therapeutics Revenue in Tumor-Specific Antigen Business (2016-2021) & (US$ Million)
Table 75. Go Therapeutics Recent Development
Table 76. Lee Biosolutions Company Details
Table 77. Lee Biosolutions Business Overview
Table 78. Lee Biosolutions Tumor-Specific Antigen Product
Table 79. Lee Biosolutions Revenue in Tumor-Specific Antigen Business (2016-2021) & (US$ Million)
Table 80. Lee Biosolutions Recent Development
Table 81. Bio-Rad Company Details
Table 82. Bio-Rad Business Overview
Table 83. Bio-Rad Tumor-Specific Antigen Product
Table 84. Bio-Rad Revenue in Tumor-Specific Antigen Business (2016-2021) & (US$ Million)
Table 85. Bio-Rad Recent Development
Table 86. Biomrieux Company Details
Table 87. Biomrieux Business Overview
Table 88. Biomrieux Tumor-Specific Antigen Product
Table 89. Biomrieux Revenue in Tumor-Specific Antigen Business (2016-2021) & (US$ Million)
Table 90. Biomrieux Recent Development
Table 91. Caris Life Sciences Company Details
Table 92. Caris Life Sciences Business Overview
Table 93. Caris Life Sciences Tumor-Specific Antigen Product
Table 94. Caris Life Sciences Revenue in Tumor-Specific Antigen Business (2016-2021) & (US$ Million)
Table 95. Caris Life Sciences Recent Development
Table 96. Roche Company Details
Table 97. Roche Business Overview
Table 98. Roche Revenue in Tumor-Specific Antigen Business (2016-2021) & (US$ Million)
Table 99. Roche Recent Development
Table 100. Abcam Company Details
Table 101. Abcam Business Overview
Table 102. Abcam Tumor-Specific Antigen Product
Table 103. Abcam Revenue in Tumor-Specific Antigen Business (2016-2021) & (US$ Million)
Table 104. Abcam Recent Development
Table 105. Merck Group Company Details
Table 106. Merck Group Business Overview
Table 107. Merck Group Tumor-Specific Antigen Product
Table 108. Merck Group Revenue in Tumor-Specific Antigen Business (2016-2021) & (US$ Million)
Table 109. Merck Group Recent Development
Table 110. PerkinElmer Company Details
Table 111. PerkinElmer Business Overview
Table 112. PerkinElmer Tumor-Specific Antigen Product
Table 113. PerkinElmer Revenue in Tumor-Specific Antigen Business (2016-2021) & (US$ Million)
Table 114. PerkinElmer Recent Development
Table 115. OriGene Technologies Company Details
Table 116. OriGene Technologies Business Overview
Table 117. OriGene Technologies Tumor-Specific Antigen Product
Table 118. OriGene Technologies Revenue in Tumor-Specific Antigen Business (2016-2021) & (US$ Million)
Table 119. OriGene Technologies Recent Development
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Tumor-Specific Antigen Market Share by Type: 2020 VS 2027
Figure 2. Coding Region Features
Figure 3. Non-Coding Region Features
Figure 4. Global Tumor-Specific Antigen Market Share by Application: 2020 VS 2027
Figure 5. Drug Discovery and Development Case Studies
Figure 6. Diagnostics Case Studies
Figure 7. Clinical and Basic Research Case Studies
Figure 8. Others Case Studies
Figure 9. Tumor-Specific Antigen Report Years Considered
Figure 10. Global Tumor-Specific Antigen Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Tumor-Specific Antigen Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Tumor-Specific Antigen Market Share by Regions: 2020 VS 2027
Figure 13. Global Tumor-Specific Antigen Market Share by Regions (2022-2027)
Figure 14. Global Tumor-Specific Antigen Market Share by Players in 2020
Figure 15. Global Top Tumor-Specific Antigen Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Tumor-Specific Antigen as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Tumor-Specific Antigen Revenue in 2020
Figure 17. Global Tumor-Specific Antigen Revenue Market Share by Type (2016-2021)
Figure 18. Global Tumor-Specific Antigen Revenue Market Share by Type (2022-2027)
Figure 19. North America Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Tumor-Specific Antigen Market Share by Type (2016-2027)
Figure 21. North America Tumor-Specific Antigen Market Share by Application (2016-2027)
Figure 22. North America Tumor-Specific Antigen Market Share by Country (2016-2027)
Figure 23. United States Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Tumor-Specific Antigen Market Share by Type (2016-2027)
Figure 27. Europe Tumor-Specific Antigen Market Share by Application (2016-2027)
Figure 28. Europe Tumor-Specific Antigen Market Share by Country (2016-2027)
Figure 29. Germany Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Tumor-Specific Antigen Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Tumor-Specific Antigen Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Tumor-Specific Antigen Market Share by Region (2016-2027)
Figure 39. China Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Tumor-Specific Antigen Market Share by Type (2016-2027)
Figure 47. Latin America Tumor-Specific Antigen Market Share by Application (2016-2027)
Figure 48. Latin America Tumor-Specific Antigen Market Share by Country (2016-2027)
Figure 49. Mexico Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Tumor-Specific Antigen Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Tumor-Specific Antigen Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Tumor-Specific Antigen Market Share by Country (2016-2027)
Figure 55. Turkey Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Tumor-Specific Antigen Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Agilent Technologies Revenue Growth Rate in Tumor-Specific Antigen Business (2016-2021)
Figure 59. Creative Diagnostics Revenue Growth Rate in Tumor-Specific Antigen Business (2016-2021)
Figure 60. Go Therapeutics Revenue Growth Rate in Tumor-Specific Antigen Business (2016-2021)
Figure 61. Lee Biosolutions Revenue Growth Rate in Tumor-Specific Antigen Business (2016-2021)
Figure 62. Bio-Rad Revenue Growth Rate in Tumor-Specific Antigen Business (2016-2021)
Figure 63. Biomrieux Revenue Growth Rate in Tumor-Specific Antigen Business (2016-2021)
Figure 64. Caris Life Sciences Revenue Growth Rate in Tumor-Specific Antigen Business (2016-2021)
Figure 65. Roche Revenue Growth Rate in Tumor-Specific Antigen Business (2016-2021)
Figure 66. Abcam Revenue Growth Rate in Tumor-Specific Antigen Business (2016-2021)
Figure 67. Merck Group Revenue Growth Rate in Tumor-Specific Antigen Business (2016-2021)
Figure 68. PerkinElmer Revenue Growth Rate in Tumor-Specific Antigen Business (2016-2021)
Figure 69. OriGene Technologies Revenue Growth Rate in Tumor-Specific Antigen Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

---